Clinical College of Ophthalmology, Tianjin Medical University, Tianjin, P.R. China; Tianjin Eye Hospital, Tianjin Key Lab of Ophthalmology and Visual Science, Tianjin, P.R. China; Nankai University Eye Institute, Nankai University Affiliated Eye Hospital, Nankai University, Tianjin, P.R. China.
Clinical College of Ophthalmology, Tianjin Medical University, Tianjin, P.R. China; Tianjin Eye Hospital, Tianjin Key Lab of Ophthalmology and Visual Science, Tianjin, P.R. China; Nankai University Eye Institute, Nankai University Affiliated Eye Hospital, Nankai University, Tianjin, P.R. China.
Prog Mol Biol Transl Sci. 2023;199:351-362. doi: 10.1016/bs.pmbts.2023.03.026. Epub 2023 Apr 27.
Retinal degenerative diseases cause blindness characterized by a progressive decline in the number and function of retinal pigment epithelium (RPE), photoreceptor cells, and ganglion cells. Such diseases include retinitis pigmentosa (RP), glaucomatous optic neuropathy, age-related macular degeneration and diabetic optic neuropathy. Recent studies have demonstrated that Müller glial cells (MGCs), an endogenous alternative source of retinal neurons, are important glial cells involved in retinal development, damage, and regeneration, making it an excellent target for retinal nerve regeneration. Although hardly differentiate into neuron cells, transplanted MGCs have been shown to induce partial recovery of visual function in experimental retinal degenerative models. This improvement is possibly attributed to the release of neuroprotective factors that derived from the MGCs. With the development of the therapeutic usage of pluripotent stem cell, application of induced pluripotent stem cells (iPSCs) or embryonic stem cells (ESCs) originated derivation of MGCs have been widely used in retinal degenerative disease model such as glaucoma and retinitis pigmentosa model. This chapter summarized the relevant research and mechanisms and provided a broader application and research prospects for effective treatments in retinal degenerative diseases.
视网膜退行性疾病导致失明,其特征是视网膜色素上皮 (RPE)、光感受器细胞和节细胞的数量和功能逐渐下降。此类疾病包括色素性视网膜炎 (RP)、青光眼视神经病变、年龄相关性黄斑变性和糖尿病性视神经病变。最近的研究表明,Müller 胶质细胞 (MGC),视网膜神经元的内源性替代来源,是参与视网膜发育、损伤和再生的重要胶质细胞,使其成为视网膜神经再生的极佳靶点。尽管 MGC 几乎不会分化为神经元细胞,但已证明移植的 MGC 可在实验性视网膜退行性病变模型中诱导部分视觉功能恢复。这种改善可能归因于源自 MGC 的神经营养因子的释放。随着多能干细胞治疗用途的发展,诱导多能干细胞 (iPSC) 或胚胎干细胞 (ESC) 衍生的 MGC 的应用已广泛用于青光眼和色素性视网膜炎模型等视网膜退行性疾病模型。本章总结了相关研究及其机制,并为视网膜退行性疾病的有效治疗提供了更广泛的应用和研究前景。